Barclays analyst Matt Miksic raised the firm’s price target on Becton Dickinson to $303 from $284 and keeps an Overweight rating on the shares. The company reported another strong quarter and increased growth guidance, the analyst tells investors in a research note. The firm continues to view Becton’s current pace of performance as both “impressive and sustainable,” driven by a combination of improved organic performance, operating efficiencies, strategic investment and portfolio management.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BDX:
- Becton Dickinson backs FY23 adjusted EPS view $12.10-$12.32, consensus $12.22
- Becton Dickinson reports Q3 adjusted EPS $2.96, consensus $2.91
- BD Reports Third Quarter Fiscal 2023 Financial Results
- Steris sees FY24 EPS $8.60-$8.80, consensus $8.68
- Becton Dickinson announces FDA clearance for BD RVP for BD Max System